News – Page 948 – Endpoints News

Turning Point tracks an impressive ORR rate in NSCLC — but shares skid lower on second look

7 years ago

Luck and unicorns? Who needs that? Santé Ventures’ new $250M fund is looking for biotech upstarts

7 years ago

Aslan doubles down on CSL drug, plots longshot rivalry with Dupixent in atopic dermatitis

7 years ago

Iovance comes back with another upbeat cancer trial update as #ASCO19 curtain raiser

7 years ago

Partnered with Genentech and Microsoft, this biotech believes it can leverage its knowledge of the immune system into ...

7 years ago

Ned Sharpless slammed with critical letter from a key Democratic Senator unhappy with e-cig policies

7 years ago

Finding a winner in VX-445, Vertex hustles CF combo to regulators on both sides of Atlantic

7 years ago

Novo's investment arm injects $67.5M in Oxford Biomedica; Abacus Medicine delays IPO plans

7 years ago

The coming glut? Cancer cell therapy trials are booming as China rivals US on new projects

7 years ago

After generating ASCO fervor, Iovance unveils plans to build $75M cell therapy manufacturing plant

7 years ago

Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology

7 years ago

Sequoia helps fuel Whole Biome's planned launch for 'medical probiotics' in $35M Series B

7 years ago

Troubled Biogen shows off its me-better approach to MS on PhIII update — but is it really just a patent play?

7 years ago

Novartis burnishes prospects for its big asthma drug with positive PhIII data from a similar treatment

7 years ago

After a short stay in the biotech world, Dietmar Berger is back in Big Pharma R&D — and he's taking a prominent ...

7 years ago

Third Rock unveils liquid biopsy biotech, leading $110M bet it can Thrive in early cancer detection

7 years ago

Novartis backs $30M round for cancer biotech; Bayer drug makes a ‘breakthrough’ at FDA

7 years ago

Ready to harvest its PD-L1, Alphamab reloads with $60M to nurture the bispecific patch

7 years ago

Amicus, Penn expand gene therapy research agreement into five-year collaboration

7 years ago

New Gilead chief O’Day axes worldwide ops chief and recruits Bristol-Myers’ Johanna Mercier for the top team

7 years ago

Amarin gets a boost from the FDA as regulators promise speedy Vascepa decision — but what about that panel review?

7 years ago

FDA should reassess postmarket trials for cancer drugs approved via accelerated pathway, researchers say

7 years ago

As #ASCO19 looms, a top analyst showers some love — and blockbuster status — on Amgen's KRAS killer

7 years ago

IPO boom: Antibody experts at Genmab outline global ambition in pitch for $500M

7 years ago

First page Previous page 945 946 947948949 950 951 Next page Last page